Ann: Imugene and Kincell Bio Announce Strategic Partnership, page-52

Good question.

The risk for me is that if they did pay for the facility and sold it cheap, this adds a little to the perceived risk that either cf33 is struggling for efficacy (combined with red flag of no AACR results), or they failed to close another deal and hence try to extend their cash.

We wont really know until they release further cf33 results, which there are many positive indicators, or close a big $ deal (which IMU haven't ever done).

Good to extended runway, and not be invovled in manufacturing (which is very management intensive).

What happens to Brad Glover and other manufacturing/operations/quality staff?

my opinion only, DYOR.

GLTA.